# A Study to Test the Safety and Tolerability of UCB0107 in Study Participants With Progressive Supranuclear Palsy (PSP)

> **NCT04185415** · PHASE1 · COMPLETED · sponsor: **UCB Biopharma SRL** · enrollment: 25 (actual)

## Conditions studied

- Progressive Supranuclear Palsy

## Interventions

- **DRUG:** bepranemab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04185415
- **Lead sponsor:** UCB Biopharma SRL
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-12-03
- **Primary completion:** 2021-11-17
- **Final completion:** 2021-11-17
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2023-12-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04185415

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04185415, "A Study to Test the Safety and Tolerability of UCB0107 in Study Participants With Progressive Supranuclear Palsy (PSP)". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT04185415. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*